E-viri
PDF
Recenzirano
Odprti dostop
-
Gauthier, Audrey; Viel, Sébastien; Perret, Magali; Brocard, Guillaume; Casey, Romain; Lombard, Christine; Laurent‐Chabalier, Sabine; Debouverie, Marc; Edan, Gilles; Vukusic, Sandra; Lebrun‐Frénay, Christine; De Sèze, Jérôme; Laplaud, David Axel; Castelnovo, Giovanni; Gout, Olivier; Ruet, Aurélie; Moreau, Thibault; Casez, Olivier; Clavelou, Pierre; Berger, Eric; Zephir, Hélène; Trouillet‐Assant, Sophie; Thouvenot, Eric
Annals of clinical and translational neurology, 20/May , Letnik: 8, Številka: 5Journal Article
We compared SimoaTM and EllaTM immunoassays to assess serum neurofilament‐light chain levels in 203 multiple sclerosis patients from the OFSEP HD study. There was a strong correlation (ρ = 0.86, p < 0.0001) between both platforms. The EllaTM instrument overestimated values by 17%, but as the data were linear (p = 0.57), it was possible to apply a correction factor to EllaTM results. As for SimoaTM, serum neurofilament‐light chain levels measured by EllaTM were correlated with age and EDSS and were significantly higher in active multiple sclerosis, suggesting that these assays are equivalent and can be used in routine clinical practice.
